US FDA panel backs Otsuka's blood pressure treatment device
22/08/2023 22:58
Aug 22 (Reuters) - A panel of U.S. Food and Drug
Administration (FDA) advisers on Tuesday recommended the use of
a device made by a unit of Otsuka Holdings 4578.T in a type of
surgery to treat high blood pressure.
The FDA panel voted 10 to 12 backing the use of the device
made by the Japanese company's unit ReCor for renal denervation,
a surgery in which nerve endings in the kidney are disrupted in
an effort to lower blood pressure.
(Reporting by Sriparna Roy in Bengaluru; Editing by Maju
Samuel)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug